ABL Bio Inc (KQ:298380) — Market Cap & Net Worth
Market Cap & Net Worth: ABL Bio Inc (298380)
ABL Bio Inc (KQ:298380) has a market capitalization of $2.25 Billion (₩3.32 Trillion) as of September 16, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #5765 globally and #134 in its home market, demonstrating a -16.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABL Bio Inc's stock price ₩59300.00 by its total outstanding shares 55987463 (55.99 Million). Also see 298380 asset base for a full breakdown of the balance sheet.
ABL Bio Inc Market Cap History: 2020 to 2026
ABL Bio Inc's market capitalization history from 2020 to 2026. Data shows growth from $1.18 Billion to $2.25 Billion (14.62% CAGR). Also see cash efficiency ratio of ABL Bio Inc for how efficiently the company converts equity into cash flow.
Index Memberships
ABL Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$231.82 Billion | 0.97% | #16 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$231.82 Billion | 0.97% | #16 of 1384 |
Weight: ABL Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ABL Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABL Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for ABL Bio Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.10x
ABL Bio Inc's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.18 Billion | $8.10 Billion | -$55.61 Billion | 0.15x | N/A |
| 2021 | $838.52 Million | $5.33 Billion | -$43.56 Billion | 0.16x | N/A |
| 2022 | $872.66 Million | $67.30 Billion | $3.21 Billion | 0.01x | 0.27x |
| 2023 | $933.37 Million | $65.55 Billion | -$2.65 Billion | 0.01x | N/A |
| 2024 | $1.13 Billion | $33.40 Billion | -$55.53 Billion | 0.03x | N/A |
| 2025 | $7.59 Billion | $79.35 Billion | -$37.81 Billion | 0.10x | N/A |
Competitor Companies of 298380 by Market Capitalization
Companies near ABL Bio Inc in the global market cap rankings as of September 16, 2026. Review ABL Bio Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ABL Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
ABL Bio Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, ABL Bio Inc's market cap moved from $1.18 Billion to $ 2.25 Billion, with a yearly change of 14.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩2.25 Billion | -70.35% |
| 2025 | ₩7.59 Billion | +568.90% |
| 2024 | ₩1.13 Billion | +21.54% |
| 2023 | ₩933.37 Million | +6.96% |
| 2022 | ₩872.66 Million | +4.07% |
| 2021 | ₩838.52 Million | -28.94% |
| 2020 | ₩1.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of ABL Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.25 Billion USD |
| MoneyControl | $2.25 Billion USD |
| MarketWatch | $2.25 Billion USD |
| marketcap.company | $2.25 Billion USD |
| Reuters | $2.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABL Bio Inc
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also … Read more